Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1 Mutation Myeloid Neoplasms”

46 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 46 results

Early research (Phase 1)Looking for participantsNCT05756777
What this trial is testing

Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07664839
What this trial is testing

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

Who this might be right for
Acute Myeloid LeukemiaNPM1 MutationIDH1 Mutation+1 more
Shen yang 148
Testing effectiveness (Phase 2)Looking for participantsNCT03471260
What this trial is testing

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaHematopoietic and Lymphoid System NeoplasmMyelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 96
Testing effectiveness (Phase 2)Looking for participantsNCT07471841
What this trial is testing

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Who this might be right for
IDH1 MutationRelapsed / Refractory AML
Timothy Pardee 25
Testing effectiveness (Phase 2)WithdrawnNCT06597734
What this trial is testing

Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Who this might be right for
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03503409
What this trial is testing

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07463768
What this trial is testing

Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

Who this might be right for
Acute Myeloid Leukemia
French Innovative Leukemia Organisation 60
Not applicableStudy completedNCT06181734
What this trial is testing

Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC

Who this might be right for
Acute Myeloid Leukemia (AML)
iOMEDICO AG 8
Not applicableUnknownNCT04369287
What this trial is testing

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIDH2 Gene Mutation
Istituto Clinico Humanitas 654
Testing effectiveness (Phase 2)Looking for participantsNCT06782542
What this trial is testing

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaIDH1 Mutation
Justin Watts, MD 16
Testing effectiveness (Phase 2)WithdrawnNCT04044209
What this trial is testing

The IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Yale University
Testing effectiveness (Phase 2)WithdrawnNCT04013880
What this trial is testing

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+3 more
Vanderbilt-Ingram Cancer Center
Early research (Phase 1)Study completedNCT03127735
What this trial is testing

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Who this might be right for
Leukemia, Myeloid, Acute
Bayer 27
Early research (Phase 1)Active Not RecruitingNCT02632708
What this trial is testing

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Who this might be right for
Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+2 more
Institut de Recherches Internationales Servier 153
Early research (Phase 1)Study completedNCT04176393
What this trial is testing

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia
CStone Pharmaceuticals 30
Testing effectiveness (Phase 2)Looking for participantsNCT06566742
What this trial is testing

Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Who this might be right for
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined Significance
M.D. Anderson Cancer Center 15
Early research (Phase 1)Ended earlyNCT04250051
What this trial is testing

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRecurrent Myeloproliferative Neoplasm+5 more
Northwestern University 2
Testing effectiveness (Phase 2)Looking for participantsNCT06668584
What this trial is testing

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

Who this might be right for
Myeloid Malignancies
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Looking for participantsNCT07607418
What this trial is testing

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Who this might be right for
AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)
Ruijin Hospital 20
Early research (Phase 1)Looking for participantsNCT02074839
What this trial is testing

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more
Institut de Recherches Internationales Servier 291
Next Page